AVXL - Anavex Life Sciences Corp Price Target Chart
The market price visualization for Anavex Life Sciences (AVXL) demonstrates the asset's dynamics while the company tests the efficacy of treatments for CNS pathologies, with research expenditures amounting to 20.00. The business operates on an asset-light model, outsourcing the production of Parkinson's disease drugs to external contractors. Long-term potential is supported by unique patents and a scientific foundation in the field of combating neurodegeneration.
Analytical breakdowns for Anavex Corp (AVXL)
- stock value and consensus price forecast:
- market capitalization statistics:
- issuer book value statistics:
- business debt structure and liquidity details:
Debt to Equity Ratio Anavex Life Sciences|AVXL - Long-Term Debt to Capital|Current Liabilities to Capital Anavex Life Sciences Corp|AVXL - Company Total Debt|Debts to Book Capitalization Anavex Corp|AVXL - Company Long-Term Debt|Company Short-Term Loans and Borrowings Anavex Life Sciences|Immediate Liquidity anavex.com
- net income and valuation multiples indicators:
AVXL - Net Profit|Projected Future Earnings Anavex Life Sciences|AVXL - Price to Earnings Ratio|Price to Future Earnings Ratio Anavex|AVXL - PEG Multiple|EV/EBITDA Multiple Anavex Corp|AVXL - Operating profit before deduction of amortization|Earnings per share for the last twelve months Anavex Life Sciences|AVXL - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months anavex.com|AVXL - Net earnings per share growth this year|Projected earnings per share growth rate for next year Anavex Life Sciences
Summary company analytics:AVXL anavex.com
Anavex Life Sciences is developing innovative treatments for neurodegeneration, potentially granting the company significant pricing power. The current consensus valuation reflects market expectations for this market capitalization. This metric aggregates independent expert forecasts, filtering out emotional price volatility. The smoothed line illustrates the fundamental target value of the business. Investors should view this trend as a benchmark for fair value, while accounting for clinical trial risks.
Competitors of Anavex Life Sciences
Analyst Consensus Forecast biogen.com (BIIB)|Neurocrine Biosciences, Inc. - Consensus Target|Regencell Bioscience Ltd - Price Target Chart|AXSM: Consensus Target|ACAD (ACADIA Corp) - Broker Consensus Forecast|Xenon Pharmaceuticals (XENE) - Price Target Chart|VKTX (vikingtherapeutics.com) - Price Target Chart|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|CeriBell Corp (CBLL) - Price Target Chart|Average Forecast Price Prothena Corporation plc (PRTA)|ALEC (Alector Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast annexonbio.com|Price Target Chart Omeros Corporation (OMER)|Neurogene Inc - Broker Consensus Forecast|Analyst Consensus Forecast ACIU (AC Immune Corp)|Analyst Consensus Forecast Voyager Corp VYGR|NMRA: Consensus Target|SCLX: Price Target Chart|TVGN: Analyst Consensus Forecast|Average Forecast Price Alpha Cognition Inc. (ACOG)|Consensus Target CGTX|Broker Consensus Forecast IKT (Inhibikase Pharma)|Consensus Target SAVA (Cassava Sciences, Inc.)|ASRT (assertiotx.com) - Fair Value Consensus|Price Target Chart Coya Therapeutics COYA|VistaGen Therapeutics, Inc. - Price Target Chart|Ovid Rx - Analyst Consensus Forecast|Analyst Median Target Acumen Pharmaceuticals, Inc ABOS|CRVO: Analyst Consensus Forecast|Forecast Levels Chart ATHE (Alterity Therapeutics Limited)|CLNN (Clene Inc) - Analyst Consensus Forecast|Average Forecast Price PepGen Corp PEPG|Consensus Target JUNS (Jupiter Neurosciences Inc)|RLMD (Relmada Corp) - Fair Value Consensus|Price Target Chart Annovis Bio, Inc. ANVS|Analyst Median Target Grace Therapeutics Inc (GRCE)|Firefly Neuroscience - Analyst Consensus Forecast|Klotho Neurosciences Inc (KLTO) - Consensus Target|NRSN: Analyst Consensus Forecast|RVPH - Analyst Median Target|MTVA (MetaVia Inc.) - Analyst Consensus Forecast|Average Forecast Price neuraxis.com NRXS|Price Target Chart Helius Medical (HSDT)|passagebio.com - Broker Consensus Forecast|Analyst Consensus Forecast NEUP (Neuphoria Therapeutics)|NERV - Consensus Target|Athira Pharma, Inc. - Analyst Consensus Forecast|Average Forecast Price addextherapeutics.com|alzamend.com (ALZN) - Price Target Chart|CYCN - Analyst Median Target|PTIX (Protagenic Therapeutics Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast Pasithea|Consensus Target CRGT (Cortigent, Inc.)|Price Target Chart ATXI (avenuetx.com)|BrainStorm Cell Therapeutics - Consensus Target|CARA: Broker Consensus Forecast|CHRO - Price Target Chart|ELYM: Price Target Chart|intracellulartherapies.com (ITCI) - Price Target Chart|Broker Consensus Forecast LBPH|MRNS (Marinus Pharmaceuticals, Inc.) - Analyst Consensus Forecast|Average Forecast Price NKGen Biotech Inc NKGN|Consensus Target NRBO (NeuroBo)|Analyst Consensus Forecast Sage Therapeutics Inc (SAGE)|Price Target Chart Synaptogenix, Inc. SNPX|Fair Value Consensus TRVN|VIGL - Price Target Chart|Average Forecast Price Anew Medical Inc.|CERE: Analyst Consensus Forecast
